GlaxoSmithKline Plc. Chairman Philip Hampton will step down after more than three and a half years in the role, as Britain’s biggest drugmaker prepares to split its business into two.
The announcement comes a month after GSK’s Chief Executive Emma Walmsley announced her boldest plans yet—to split the company into two businesses—one for prescription drugs and vaccines, the other for over-the-counter products.
